Seoul, South Korea

Sudhakar Rao Kota


Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 2011-2018

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Sudhakar Rao Kota: Innovator in Medical Treatments

Introduction

Sudhakar Rao Kota is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of medicine, particularly in the treatment of serious health conditions. With a total of three patents to his name, Kota's work focuses on innovative methods that address critical medical challenges.

Latest Patents

Kota's latest patents include groundbreaking inventions aimed at treating fibrosis, cancer, and vascular injuries. One of his notable inventions involves the use of inhibitors of the transforming growth factor-β (TGF-β) type I receptor (ALK5) and/or the activin type I receptor (ALK4) in treating, preventing, or reducing these serious health issues. Another significant patent features 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors. This invention relates to the preparation and medical application of these inhibitors, specifically targeting diseases mediated by these receptors.

Career Highlights

Kota is affiliated with the Ewha University-Industry Collaboration Foundation, where he continues to advance his research and innovations. His work has garnered attention for its potential to improve treatment options for patients suffering from various medical conditions.

Collaborations

Kota collaborates with esteemed colleagues, including Dae-Kee Kim and Yhun Yhong Sheen, to further enhance the impact of his research and inventions.

Conclusion

Sudhakar Rao Kota's contributions to medical innovation are noteworthy, as he continues to develop solutions that could transform treatment methodologies for critical health issues. His dedication to research and collaboration underscores the importance of innovation in the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…